Literature DB >> 26971846

Surgical management of neuroendocrine tumors.

Domenico Tamburrino1, Gabriele Spoletini2, Stefano Partelli3, Francesca Muffatti4, Olga Adamenko5, Stefano Crippa6, Massimo Falconi7.   

Abstract

During the last decades an increase in the incidence of neuroendocrine tumors (NETs) was observed. Gastroenteropancreatic NETs represent the majority of NETs. Compared with their epithelial counterpart they usually have a more indolent behaviour and surgical resection improves survival. Tumor diameter is one of the main parameter in the decision making process for nonfunctioning forms. Generally, small lesions can be treated conservatively whereas larger tumors should be treated with standard surgical resection and lymphadenectomy. Functioning tumors should be resected regardless the dimension of the lesion. Locally advanced and metastatic disease should be also treated with extended resections, keeping in consideration the grading, size, Ki67, and presence of extra-abdominal disease. In the case of metastases the panel of operative treatment includes resection, ablation, up to liver transplantation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MEN 1; carcinoid; liver metastases; neuroendocrine tumors; surgery

Mesh:

Year:  2015        PMID: 26971846     DOI: 10.1016/j.beem.2015.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  8 in total

Review 1.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 2.  [Early endocrine neoplasia of the pancreas].

Authors:  V Fendrich; D K Bartsch
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

4.  Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Authors:  Andrew E Hendifar; Samuel H Mehr; Derek R McHaffie
Journal:  Pancreas       Date:  2022-03-01       Impact factor: 3.243

Review 5.  Surgical Therapy of Sporadic Pancreatic Neuroendocrine Neoplasias G1/G2.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Visc Med       Date:  2017-10-04

6.  Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Rossana Berardi; Mariangela Torniai; Stefano Partelli; Corrado Rubini; Silvia Pagliaretta; Agnese Savini; Vanessa Polenta; Matteo Santoni; Riccardo Giampieri; Sofia Onorati; Federica Barucca; Alberto Murrone; Francesca Bianchi; Massimo Falconi
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

7.  Transduodenal resection of periampullary neuroendocrine tumor: A case report.

Authors:  Abdullah Abdulaziz AlQatari; Rania Zaki Fallatah; Abdullah Saleh AlQattan; Alaa A Al Abdrabalnabi; Miral Mashhour; Abdulwahab A AlShahrni
Journal:  Ann Med Surg (Lond)       Date:  2021-12-29

8.  Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.

Authors:  Ashley L Titan; Jeffrey A Norton; Andrea T Fisher; Deshka S Foster; E John Harris; David J Worhunsky; Patrick J Worth; Monica M Dua; Brendan C Visser; George A Poultsides; Michael T Longaker; Robert T Jensen
Journal:  JAMA Netw Open       Date:  2020-11-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.